Clinical Trial Update: Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 multicenter trial of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection in advanced colorectal cancer completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection (Irinotecan HCl: Floxuridine liposome)

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2021-07-02